Tyra Biosciences (NASDAQ:TYRA - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Tyra Biosciences to post earnings of ($0.49) per share for the quarter.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.05. On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Tyra Biosciences Stock Performance
NASDAQ:TYRA traded up $0.38 during trading hours on Friday, hitting $10.86. The stock had a trading volume of 394,236 shares, compared to its average volume of 253,816. The business's 50 day moving average is $9.80 and its 200-day moving average is $13.82. The company has a market cap of $576.56 million, a price-to-earnings ratio of -6.75 and a beta of 1.19. Tyra Biosciences has a one year low of $6.42 and a one year high of $29.60.
Wall Street Analyst Weigh In
Several analysts recently commented on the company. Wedbush reaffirmed an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. UBS Group initiated coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $30.83.
Read Our Latest Stock Report on TYRA
Insider Activity
In other news, Director Nina S. Kjellson sold 5,401 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the transaction, the director now directly owns 443,885 shares of the company's stock, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 15.40% of the company's stock.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Recommended Stories
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
